Kestra Medical Technologies (NASDAQ:KMTS) Sets New 52-Week High – Still a Buy?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $26.15 and last traded at $24.35, with a volume of 152464 shares changing hands. The stock had previously closed at $24.13.

Analyst Ratings Changes

Several equities analysts have issued reports on KMTS shares. Bank of America began coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued a “buy” rating and a $30.00 price target for the company. The Goldman Sachs Group decreased their target price on Kestra Medical Technologies from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Wednesday. Wolfe Research assumed coverage on shares of Kestra Medical Technologies in a research note on Monday, March 31st. They issued an “outperform” rating and a $29.00 price target for the company. Stifel Nicolaus initiated coverage on Kestra Medical Technologies in a report on Monday, March 31st. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Piper Sandler initiated coverage on shares of Kestra Medical Technologies in a research report on Monday, March 31st. They issued an “overweight” rating and a $27.00 price target for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $27.50.

Kestra Medical Technologies Stock Performance

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Monday, April 14th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.61). During the same period last year, the firm posted ($1.18) EPS.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.